我們已在上線！進一步了解

Lineage Cell Therapeutics

LCTX

市值 US$2.47億

0.9783 USD

-0.0120

1.21%

收盤時已更新 10月16日下午4:00 EDT

盤前交易

盤後交易

0.9783

0.0000

0%

1天

-1.21%

5天

-1.96%

1個月

-8.57%

3個月

-16.38%

6個月

-40.35%

今年迄今

-40.35%

1年

-42.45%

5年

-57.09%

10年

-68.13%

關於： Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.

員工： 77

醫療保健藥品製造商－一般

新聞

正面

中性

負面

市場情緒 3個月

正面 16.7%

中性 83.3%

負面 0%

Lineage Cell Therapeutics Announces Issuance of Patent Underlying Its AlloSCOPE™ 5D Manufacturing Platform

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--AlloSCOPE 5D Patent Release.

Lineage Cell Therapeutics Announces Issuance of Patent Underlying Its AlloSCOPE™ 5D Manufacturing Platform

Lineage Cell Therapeutics Q2 Earnings Call Highlights

Lineage Cell Therapeutics NYSEAMERICAN: LCTX outlined progress across its cell-therapy pipeline during its second-quarter 2026 earnings call, highlighting preclinical advances in corneal disease, Type 1 diabetes and hearing loss programs while Roche and Genentech continue surgical-delivery optimization work for its lead OpRegen program.

Lineage Cell Therapeutics Q2 Earnings Call Highlights

Lineage Cell Therapeutics, Inc. (LCTX) Q2 2026 Earnings Call Transcript

Lineage Cell Therapeutics, Inc. (LCTX) Q2 2026 Earnings Call Transcript

Lineage Cell Therapeutics, Inc. (LCTX) Q2 2026 Earnings Call Transcript

Zacks Investment Research

Lineage Cell (LCTX) Reports Q2 Loss, Lags Revenue Estimates

Lineage Cell (LCTX) came out with a quarterly loss of $0.03 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.01 per share a year ago.

Lineage Cell (LCTX) Reports Q2 Loss, Lags Revenue Estimates

Lineage Cell Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Q2 2026 Earnings Release.

Lineage Cell Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Lineage Cell Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel, allogeneic, “off the shelf”, cell therapies for serious medical conditions, today announced that it will report its second quarter 2026 financial and operating results on August 6, 2026, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on August 6, 2026, at 4:30 p.m. Eastern Ti.

Lineage Cell Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026

Lineage Cell Therapeutics Maps COR1 Path With ‘Thaw and Inject' Cell Therapy Plan

Lineage Cell Therapeutics NYSEAMERICAN: LCTX used a conference call to outline its manufacturing strategy and development plans for COR1, a wholly owned preclinical cell transplant program being developed as a potential treatment for corneal endothelial disease.

Lineage Cell Therapeutics Maps COR1 Path With ‘Thaw and Inject' Cell Therapy Plan

Lineage Cell Therapeutics, Inc. (LCTX) Discusses COR1 Cell Transplant Program and Manufacturing Strategy for Corneal Endothelial Disease Transcript

Lineage Cell Therapeutics, Inc. (LCTX) Discusses COR1 Cell Transplant Program and Manufacturing Strategy for Corneal Endothelial Disease Transcript

Lineage Cell Therapeutics, Inc. (LCTX) Discusses COR1 Cell Transplant Program and Manufacturing Strategy for Corneal Endothelial Disease Transcript

Lineage Provides Update on COR1 Cell Therapy Program for Corneal Endothelial Disease

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel, allogeneic, “off the shelf”, cell therapies for serious medical conditions, today provided an update on COR1, the Company's allogeneic corneal endothelial cell (CEnC) transplant program, in preclinical development for the treatment of corneal endothelial disease. With COR1, Lineage is deploying its ophthalmology and cell manufacturing expert.

Lineage Provides Update on COR1 Cell Therapy Program for Corneal Endothelial Disease

Lineage Cell Therapeutics to Present at B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing “off the shelf” allogeneic cell therapies for serious medical conditions, today announced that Brian M. Culley, Lineage's Chief Executive Officer, will be presenting at the B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit, in a fireside chat hosted by Mayank Mamtani, Senior Managing Director, Group Head of Healthcare Research an.

Lineage Cell Therapeutics to Present at B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit

查看新聞排名

價格圖表採用Lightweight Charts™實作